摘要
目的:探讨乳腺癌患者手术前后血清CA153、CA125和CEA水平的变化。方法:应用化学发光免疫分析法(CLIA)检测168例乳腺癌(Ⅰ+Ⅱ期125例,Ⅲ+Ⅳ期43例)患者血清CA153、CA125和CEA含量,并与132例非肿瘤患者作比较。结果:乳腺癌患者手术治疗前血清CA153、CA125和CEA含量非常显著地高于非肿瘤患者组(P<0.01);三者联合检测较单一检测阳性率明显增高(P<0.01)。Ⅰ+Ⅱ期患者手术后3个月CA153、CA125和CEA水平下降(P<0.05),与非肿瘤患者组比较无显著性差异(P>0.05);Ⅲ+Ⅳ期患者手术后3个月CA153、CA125和CEA水平明显下降(P<0.05),但仍高于非肿瘤患者组(P<0.05)。结论:检测乳腺癌患者血清CA153、CA125和CEA含量对临床诊断和预后观察具有重要的临床价值。
Objective ： To investigate changes of serum CA153, CA125 and CEA levels after operation in patients with breast cancer. Methods：Serum CA153, CA125 and CEA levels were measured by CLIA in 168 patients with breast cancer（Ⅰ or Ⅱ 125, Ⅲ or Ⅳ 43） both before and 3 months after operation. While 132 controls also underwent these detection. Results： Before operation,in the patients the serum CA153,CA125 and CEA levels were significantly higher than those in the controls（P〈0.01）. The positive rate of Combined determination of serum CA153, CA125, CEA was higher than that in single determination（P〈0.01）. Three months after operation,the serum （Ⅰ or Ⅱ ） CA153,CA125 and CEA levels dropped markedly（P〈0.05）and were not significantly different from those in controls（P〉0.05）. Three months after operation the serum （Ⅲ or Ⅳ） CA153,CA125 ,CEA levels dropped markedly（P〈0.05）,but were still higher than those in controls （P〈0.05）. Conclusion： Detection of serum CA153, CA125 and CEA levels is valuable for the diagnosis and outcome prediction in patients with breast cancer.
出处
《实用临床医学（江西）》
CAS
2007年第6期103-105,共3页
Practical Clinical Medicine
